E-mail:BD@ebraincase.com
Tel:+8618971215294
English 中文版
Virus Vector - Viral Vector Production - BrainCaseVirus Vector - Viral Vector Production - BrainCase
  • Home
  • Virus product library
    CRISPRRNAiHSV-helperRV-helperNeurophilic virusCalcium SensorsOptogenetics activationOptogenetics inhibitionChemical geneticsSparse labelingFluorescent proteinBiosensorsRecombinaseApoptosis & AutophagyDisease ModelNeurotoxicityOther
  • Products & Service

    Product Center

    Virus

    VSV-circuit research-vaccine and gene therapy research-BrainCase
    Retrovirus-RCAS-TVA-BrainCase
    Lentivirus Vector - Lentivirus Production - BrainCase
    Rabies Virus Vector - RBV Vector - BrainCase
    Herpes simplex virus-Oncolytic and anterograde tracing-Brain Case
    PRV-retrograd multisynaptic-Peripheral-Btain Case
    AAV-gene therapy vectors-BrainCase

    Animal Model

    Neurological Disease Models-BrainCase
    Tumor animal models-anti-tumor-BrainCase
    Digestive System Disease Animal Model-Brain Case
    Cardiovascular System Disease Animal Models-Brain Case

    Plasmid Construction

    Library Construction
    Plasmid design and construction

    Popular Applications

    Gene Regulation

    Gene Overexpression-Brain Case
    RNA interference(RNAi)-siRNA-Brain Case
    Gene Editing - CRSIPR cloning - BrainCase

    Neural Circuit Function Research

    Optogenetics - BrainCase
    Chemical genetics-DREADDs-Brain Case
    Calcium signal recording-Gels- Brain Case
    GRAB Neurotransmitter Fluorescent Sensor- Brain Case
    Functional Magnetic Resonance Imaging Technology- Brain Case

    Research on the structure of neural circuits

    Direct Input and Output-viral vectors- Brain Case
    Anterograde Mono-synaptic Tracing -HSV- Brain Case
    Antrograde Muti-synaptic Tracing-HSV & VSV-Brain Case
    Retrograde Mono-synaptic Tracing-Rabies Virus-Brain Case
    Retrograde Muti-synaptic Tracing-PRV-Brain Case

    Featured Services

    Nervous System Disease Drug Effect

    Alzheimer's disease-AD-Brain Case
    Depression-mental disorders-Brain Case
    Parkinson's disease--PD-Brain Case
    Epilepsy-an ancient neurological disorder-Brain Case

    AAV Serotype Screening

    AAV Serotypes screening-gene therapy-Brain Case

    Tumorigenicity Test

    Tumorigenicity Testing-Evaluation of tumor models-Brain Case

    Efficacy of Oncolytic Virus

    Oncolytic virus-for cancer therapy-Brain Case
    Herpes Virus Vector-anti-tumor- BrainCase
    Vesicular stomatitis virus-killing tumor cells-Brain Case
  • News
    Corporate News New Product Launch Media Activity Investor News
  • Support
    Literature interpretation Customer article Video Zone FAQs
  • About Us
    Virus product library Products & Service News Support About Us Contact
  • Contact
    Contact Us Join us
  • 中文
    English 中文版
  • Home
  • Support
  • FAQs
  • Learning Center
  • FAQs
  • Animal experiments
  • Gene Regulation
  • Neural-circuit
  • Cell Experiments
  • Learning Center

Learning Center

  • Q1: What are the factors that affect RNA interference efficiency?

    A:

    ①Differences in structure (double-stranded RNA has higher potency than single-stranded RNA), Similar behavior of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway ( https://academic.oup.com/nar/article /31/9/2401/1080348)(http://europepmc.org/article/PMC/154224 ) ; _

    ②Difference in sequence,

    ③Differences in mRNA position, https://www.biomart.cn/experiment/430/443/450/680/2282559.htm

  • Q2: What factors need to be considered when designing stable strain construction experiments?

    A: Several key factors that need to be considered in a stable integration test are:

    1) The copy number of the exogenous inserted fragment. In most cases, low copy or even single copy can reduce the interference of human experimental factors;

    2) The probability of integration, which not only determines the difficulty of screening stable strains, but also makes it easier to obtain mixed stable strains;

    3) The transcription activity of the integration site determines the expression quality of the foreign fragment in the stable strain;

    4) Stability after integration. Different integration sites determine the stability of exogenous fragments in the chromosome. Some regions are prone to recombination or loss, resulting in the loss of stable strains again;

    5) Use mixed stable strains or obtain multiple different monoclonal stable strains. Because stable integration is often accompanied by insertional inactivation of host endogenous genes, using mixed stable strains or comparing multiple monoclonal stable strains during experiments can help obtain more accurate experimental data. ( https://wenku.baidu.com/view/306486dc6f1aff00bed51e78.html )

  • Q3: What are the factors that affect siRNA transfection efficiency?

    A: ( https://zhuanlan.zhihu.com/p/100352316 )

  • Q4: How to solve the problem of high toxicity of lipofectamine transfection reagent?

    A: https://zhuanlan.zhihu.com/p/29140323

  • Q5: In virus-infected cell experiments, what is the reason for cytotoxicity when using infection enhancers?

    A:

    ① If the dosage of enhancer is too large, its dosage can be appropriately reduced;

    ② If the amount of virus is too large, the amount of virus can be appropriately reduced, and the method of changing the culture medium or increasing the amount of culture medium can be used. ( https://zhuanlan.zhihu.com/p/126995361 )

  • Q6: What is the appropriate amount of cell inoculation for virus infection?
    A: Determine the inoculation amount based on the cell proliferation rate. Generally, it is necessary to ensure that the cells almost cover the bottom of the culture dish about 4 days after infection. For most cell lines: the passage period is 2-3 days, and the cell plating density during infection should be maintained within the range of 20%-30%. For some primary cells: cells grow slowly, and the confluency can be increased to 50%-60% during inoculation, ensuring that the cell confluence reaches 90%-100% about 4 days after infection. For non-dividing cells that no longer proliferate after inoculation (such as neuronal cells), inoculate at 100% confluence.
  • Q7: After adding the virus, the cells died seriously. What is the reason? How to deal with it?
    A: Generally, viruses have certain toxicity to cells, and the infection MOI can be adjusted and lowered. And pay close attention to the cell status, and observe the cell status regularly at 4, 8, and 12 hours after infection. If the cell status deteriorates, immediately change the medium of the cells and replace the virus-infected culture medium with fresh complete culture medium.
  • Q8: How to improve virus infection efficiency?
    A: The efficiency of virus infection is affected by many factors, including the growth status of the cells themselves, the number of cells, and the ease of infection of the cells. Therefore, during the experiment, ensuring normal cell proliferation and clear outlines while maintaining appropriate cell density and selecting optimal infection conditions can better ensure infection efficiency. For suspension cells, centrifugal infection can be used to reduce the volume of virus infection and thereby improve the infection efficiency. If the culture plate is sealed, centrifuge it with a square-angle rotor centrifuge at 1000 g for 1 hr, and then put it back into the incubator to continue normal culture.
  • Q9: Cells can be infected by viruses, but why is GFP fluorescence so weak?
    A: After the GFP virus infects cells, the fluorescence intensity of the cells depends on the number of virus particles entering the cells, the proliferation status of the cells themselves, cell type, observation time, GFP gene promoter activity and other factors. Therefore, the more viral particles the target cells are infected with and the faster the cells proliferate, the stronger the GFP fluorescence will be. Generally, GFP protein expression reaches its peak 96-120 hrs after virus infection in cells that proliferate quickly; in cells that proliferate slowly, this time is longer. The fluorescent expression of the GFP gene behind a strong promoter is strong, and conversely, the fluorescent expression behind a weak promoter is weak.
  • Q10: What are the factors affecting cell transfection experiments?

    A: https://zhuanlan.zhihu.com/p/29100441

  • Q11: How is the time specificity of conditional gene knockout achieved?

    A:https://www.sohu.com/a/200476821_100007412

map
{dede:global.cfg_webname/}

Virus product library

CRISPR
RNAi
Neurophilic virus
Optogenetics activation
Biosensors

News

Corporate News
New Product Launch
Media Activity
Investor News

Support

Literature interpretation
Customer article
Video Zone
FAQs
微信

WhatsApp Business Account

Tel: +8618971215294
E-mail: BD@ebraincase.com

Address:-

Address:-

  • Copyright © 2024 Brain Case All Rights Reserved.